Almirall Exercises its Option to License Dermira’s Lebrikizumab for Atopic Dermatitis in Europe

 Almirall Exercises its Option to License Dermira’s Lebrikizumab for Atopic Dermatitis in Europe

Almirall Exercises its Option to License Dermira’s Lebrikizumab for Atopic Dermatitis in Europe

Shots:

  • Dermira to receive $50M as an option exercise fee, $30M milestone with the initiation of P-III studies, $85M as the regulatory & commercial milestone and royalties on sales. Almirall to get development & commercialization rights of lebrikizumab for atopic dermatitis & other indications in Europe
  • In Feb’19, Almirall and Dermira entered into an option and license agreement and exercise of the option follows P-IIb study results which demonstrated in meeting its 1EPs and a dose-dependent improvement in patients with moderate-to-severe atopic dermatitis
  • Lebrikizumab is mAb, binds with IL-13 to prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex thereby inhibiting the biological effects of IL-13 with its expected initiation of P-III study in H2’19

Click here to read full press release/ article | Ref: Almirall | Image: Investor Place

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post